Karyon, Ltd. develops peptides into carriers for use in cancer diagnostics, imaging, and therapy. It offers Karyon Targeting Unit, a synthetic peptide that targets specific tumor tissue. The company engages in the areas of cancer biology and cell growth regulation, angiogenesis, biochemistry, peptide chemistry, organic syntheses and immunohistochemistry. Karyon, Ltd. was founded in 2001 and is based in Helsinki, Finland. As of May 6, 2008, Karyon Ltd. operates as a subsidiary of Isogenica Limited.